Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis


The primary aim of the study was to evaluate the long-term effectiveness of adalimumab (ADA) in a cohort of non-radiographic axial spondyloarthritis (nr-axSpA), and the secondary aims were to identify predictive factors of response and evaluate radiological progression.We evaluated 37 patients (male/female: 12/25; mean age 49 ± 14; mean disease duration: 6.3 ± 5.8) with active nr-axSpA (Assessment of SpondyloArthritis International Society criteria), despite the treatment with ≥1 nonsteroidal anti-inflammatory drug for at least 3 months, initiating the treatment with ADA 40 mg every other week. Patients were treated for 24 months, and evaluated at baseline, 6, 12, and 24 months. Outcome measures included Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index. Radiograph of the spine and sacroiliac joints and magnetic resonance of the sacroiliac joints were performed at baseline and according to the standard of assessment for the disease.The proportion of patients that achieved a BASDAI50 response at 6, 12 and 24 months was 51.3%, 70.3%, and 76.8%, respectively. Treatment was well tolerated with no unexpected adverse events and/or serious adverse events. All patients remained on treatment for 2 years, with a good compliance. We did not identify any predictive factor of response to therapy. Moreover, modified Stoke Ankylosing Spondylitis Spine Score and Spondyloarthritis Research Consortium of Canada scores showed a trend of improvement during the study period.ADA was effective on clinical and radiological outcomes at 2-year follow-up; thus, early treatment with ADA may prevent radiographic damage and be associated with low disease activity or remission. Moreover, data from this cohort study have confirmed safety and tolerability profile of ADA in nr-axSpA in the long term.

DOI: 10.1097/MD.0000000000001170

Extracted Key Phrases

3 Figures and Tables

Citations per Year

163 Citations

Semantic Scholar estimates that this publication has 163 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Cantarini2015EffectivenessOA, title={Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis}, author={Luca Cantarini and Marta Fabbroni and Rosaria Talarico and Lu{\'i}sa Beir{\~a}o - Costa and Francesco Caso and Gian Luca Cuneo and Bruno Frediani and Gabriele Faralli and Antonio Vitale and Maria Giuseppina Brizi and Luciano Sabadini and Mauro Galeazzi and Omboni. Stefano}, booktitle={Medicine}, year={2015} }